[Hot Stock] IM Biologics Surges 300% on First Day of KOSDAQ Listing
IM Biologics succeeded in achieving a "Tta-Tta-Ble" (a quadruple increase from the IPO price) on its first day of trading on the KOSDAQ.
As of 9:07 a.m. on March 20, IM Biologics was trading at 104,000 won, up 300% from its IPO price of 26,000 won.
IM Biologics set its IPO price at the upper end of the desired price band, 26,000 won, after recording a competition ratio of 839.23 to 1 in the institutional investor book-building process held from February 27 to March 6. Subsequently, the public subscription conducted on March 11-12 saw a competition ratio of 1,806 to 1. Approximately 11.7 trillion won was collected as subscription deposits.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Founded in 2020, IM Biologics is a biopharmaceutical company developing antibody drugs targeting autoimmune diseases. Recognized for the value of its pipeline based on its proprietary platform technology, the company received A and A ratings from two professional evaluation agencies in July last year, successfully passing the technology evaluation threshold.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.